Tula Reveals Technology to Reduce CO2 by 11% in Mild Hybrid Diesel Vehicles
28.6.2021 11:00:00 EEST | Business Wire | Press release
Tula Technology, Inc., a leader in propulsion efficiency, has released the findings of a recent simulation study to evaluate the efficacy of its newest technology. The study validated that Tula’s Dynamic Skip Fire (DSF) developed for mild hybrid diesel vehicles reduced CO2 emissions in a 2.3 liter 4-cylinder 48-volt light commercial vehicle in challenging real-world conditions. When Tula’s software strategies were implemented, an additional 11% of CO2 was eliminated compared to industry-leading hybrid powertrains. The CO2 reduction can be achieved at a cost of only €200 ($235 USD) per vehicle.
For manufacturers of light duty commercial vehicles, this technology offers a compelling and cost-effective solution to achieve challenging Euro 7 emission standards expected to go into effect by 2026 for all new vehicles in Europe.
“We created a synergistic technology by combining mild hybrid powertrain controls with our diesel Dynamic Skip Fire, which has proven to be very effective at reducing NOX (nitrogen oxides) and CO2 (carbon dioxide) emissions in heavy duty trucks,” said R. Scott Bailey, president and CEO of Tula Technologies. “We call it electrified diesel Dynamic Skip Fire, or edDSF, and it will help manufacturers of light commercial vehicles meet challenging NOX standards in a cost-effective manner. Equally significant, our product performs even better in tougher real-world conditions than under test cycles.”
FEV, an international engineering partner to the auto industry, joined forces with Tula to develop this study. Tula will present the results at the virtual Diesel Powertrains 3.0 Conference (https://fev-live.com/diesel/conference-program/) Wednesday, June 30, at 10:35 Paris (CEST) / 16:35 Beijing.
The findings show that electrified diesel Dynamic Skip Fire (edDSF) can significantly reduce CO2 output through the synergies created by pairing a hybrid system with DSF while also providing a means to achieve upcoming low-NOX targets aimed at decreasing the pollution created by internal combustion engines. Fuel savings are an additional benefit of edDSF compared to other emissions management technologies that typically require burning additional fuel to produce the heat required to decrease tailpipe emissions. The economics of edDSF are compelling—over a six-month period, an urban delivery vehicle equipped with edDSF will save enough in fuel expenses to recoup the costs associated with Tula’s technology.
Bailey concluded, “We are excited to present our findings at this global conference. With edDSF, we are offering a leading-edge solution to help meet the tight deadline the EU has set to reduce emissions, and for vehicle powertrain development, 2026 is just around the corner. edDSF is one of the many patented technologies in Tula’s portfolio that help improve the environment by increasing the efficiency of engines and motors while reducing harmful emissions. I am very proud of our outstanding engineering team for continuing to develop new applications for our state-of-the art control technologies.”
About Tula Technology, Inc.
Silicon Valley-based Tula Technology provides innovative award-winning software controls to optimize propulsion efficiency and emissions across the mobility spectrum, including gasoline-powered, diesel, alternative fuel, hybrid, and electric vehicles. Tula’s culture of innovation has resulted in breakthrough technology and a robust global patent portfolio of more than 340 patents issued and pending. Tula Technology is a privately held company backed by Sequoia Capital, Sigma Partners, Khosla Ventures, GM Ventures, BorgWarner and Franklin Templeton. More information is available at www.tulatech.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005183/en/
Contact information
Tula Technology, Inc.
Ram Subramanian
Principal Marketing Strategist
ram@tulatech.com
Media:
Financial Profiles, Inc.
Debbie Douglas
Senior Vice President
ddouglas@finprofiles.com
(949) 375-3436
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-making. However, compared to Riskified’s agentic commerce pulse survey in Q4 2025, consumer sentiment has shifted, with growing concerns around fraud, security, and accountability slowing the path to fully autonomous, agent-driven transactions. Key findings from th
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 15:00:00 EEST | Press release
Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environment. The findings highlight a growing disconnect between ambition and execution. Cross-border transactions are expected to form a significant portion of deal pipelines, with 47% of respondents expecting them to account for between 26% and
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼ REZZAYO ® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 14:43:00 EEST | Press release
Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing allogeneic HSCT face prolonged periods of immunosuppression and routinely require extended antifungal prophylaxis,1 representing a setting where differentiated dosing, improved side effect profile, and reduced DDI is beneficial, and comparable efficacy is expected. The ReSPECT study met its primary endpoint for US Food and Drug Administration (FDA) and European Medicines
tesa Selects Kinaxis as the Digital Backbone for Global Integrated Business Planning Transformation27.4.2026 14:00:00 EEST | Press release
Kinaxis® (TSX: KXS), a global leader in end‑to‑end supply chain orchestration, today announced that tesa SE, a global manufacturer of adhesive tapes and self-adhesive product solutions, has selected the Kinaxis Maestro™ platform as a core enabler of its global, multi‑year supply chain and integrated business planning (IBP) transformation. Following an extensive evaluation, tesa selected Kinaxis to support its evolution from regionally fragmented planning practices toward a centrally governed, globally orchestrated IBP operatingmodel. Kinaxis will support tesa in improving enterprise-wide transparency, strengthening resilience, and enabling faster, more informed decision making across an increasingly complex and volatile global supply chain network. With 130 years of innovation, tesa is one of the world’s leading manufacturers of adhesive tapes and self-adhesive product solutions. Operating across six global regions and serving both complex industrial and fast-moving consumer markets, t
vVARDIS Announces Investment from Apollo —Achieves Unicorn Status27.4.2026 14:00:00 EEST | Press release
vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulations clinically proven to treat tooth decay. Curodont™ supports en
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom